Guangzhou Innogen Pharmaceutical Group Co., Ltd
Research Guangzhou Innogen Pharmaceutical Group Co., Ltd (2591.HK) on Bullrun: market cap HKD 1.67B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker2591.HK
- ExchangeHK
- CountryChina
- SectorHealthcare
- IndustryBiotechnology
- CurrencyHKD
- Market capHKD 1.67B
- Financial periodFY2025
- RevenueCNY 131.51M
- Net income-CNY 341.36M
- Free cash flow-CNY 317.57M
- Gross margin89.0%
Valuation Snapshot
latest market cap is HKD 1.67B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 131.51M | -CNY 341.36M | -CNY 317.57M | 89.0% | n/a | CNY 969.32M | CNY 166.26M | CNY 1.05B |
| FY2024 | CNY 0 | -CNY 174.69M | -CNY 166.95M | n/a | -0.38 | CNY 526.54M | CNY 9.90M | CNY 796.47M |
| FY2023 | CNY 0 | -CNY 733.38M | -CNY 176.79M | n/a | -1.61 | CNY 407.67M | CNY 46.59M | CNY 705.13M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | HKD 1.67B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 HKD.
About Guangzhou Innogen Pharmaceutical Group Co., Ltd
Guangzhou Innogen Pharmaceutical Group Co., Ltd engages in the development of drug engaged in the research, development and commercialization of pharmaceutical products. The company's products are used for the treatment of metabolic diseases, including diabetes, obesity and overweight, and MASH; and other major central nervous system diseases. The company was incorporated in 2014 and is based in Shanghai, China.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Guangzhou Innogen Pharmaceutical Group Co., Ltd's market cap?
Guangzhou Innogen Pharmaceutical Group Co., Ltd's market capitalization is HKD 1.67B.
What does Guangzhou Innogen Pharmaceutical Group Co., Ltd do?
Guangzhou Innogen Pharmaceutical Group Co., Ltd engages in the development of drug engaged in the research, development and commercialization of pharmaceutical products. The company's products are used for the treatment of metabolic diseases, including diabetes, obesity and overweight, and MASH; and other major central nervous system diseases. The company was incorporated in 2014 and is based in Shanghai, China.